| Name | Title | Contact Details |
|---|
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck`s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company`s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.
Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs
Elco Laboratories Inc is a University Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
braunmedical is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ZymoGenetics is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.